Recently, liangyihui, an innovative digital medical platform in the field of cancer, announced the completion of a C + round of financing of hundreds of millions of yuan.

Before, many head capital in the medical field were optimistic about the business model and operation capacity of liangyihui. In this round, liangyihui will introduce a head investment institution and a head investment institution in the field of intelligent hardware as capital, which will inject more resources and capabilities into the development of liangyihui. In this round of financing, Qiming venture capital, Danlu capital and other old shareholders continue to follow the investment. Haoyue capital acted as the financial adviser of this round of financing.

At the beginning of the year, liangyihui just completed the c-round financing of more than 100 million yuan. This financing will help liangyihui further consolidate the existing tumor innovation digital platform driven by technology, data and services, deeply link hospitals, associations, doctors, tumor patients and pharmaceutical enterprises, and accurately match the demand and supply of all parties in the process of tumor drug research and development and disease treatment, Finally, let tumor patients obtain more suitable diagnosis and treatment schemes, as well as more perfect diagnosis and treatment service experience.

Founded in 2015, liangyihui has accumulated nearly 200000 oncologists and nearly 300000 cancer patients. It has become the largest online cancer doctor-patient platform in China and a trusted partner of cancer doctors and patient enterprises. At the same time, liangyihui goes deep into major cancer hospitals to help hospitals educate and manage patients. Over the past six years, liangyihui has experienced content leading, technological innovation and data driving, and has become the preferred online platform for cancer doctor-patient enterprises.

picture

With the listing and rising stock prices of doctor platforms represented by yimaitong and doximity, the value of a number of vertical doctor platforms that have cultivated internal skills for many years has gradually attracted market attention. Haoyue capital is very optimistic about the opportunities for the commercialization of new generation medical services and drugs. With the approval of innovative drugs, as well as new digital therapies and innovative devices, the efficiency of the traditional offline promotion mode is no longer satisfied with the current form of commercial competition. Pharmaceutical and mechanical enterprises will rely more on online promotion. The vertical emerging internet medical service providers represented by liangyihui have more advantages in understanding the needs of the industry, going deep into all links of the industry and providing more professional services, and it is easier to realize commercialization.

Liangyihui said that years of hard work in the field of cancer has made us have a personal experience of the needs and pain points / difficulties of clinical management. We have always been committed to providing tumor patients with a wider coverage, more convenient and most sustainable effective diagnosis and treatment methods. Tumor is not only the most important disease threatening public health, but also the hottest and most promising subject of new drug research and development. Over the years, liangyihui has adhered to and focused on building a professional vertical platform for oncology, gathered professional participants in all fields, and is committed to building the most comprehensive learning and IP platform for oncologists, providing the most accessible medical services for patients and the most complete marketing scheme for pharmaceutical enterprises.

Ms. Lu Qinchao, founding and executive partner of Danlu capital, said that with her competitive advantage in the field of tumor digital marketing, liangyihui's performance has increased rapidly in recent years. At the same time, we also recognize the company's positive attempts in other business units and believe that liangyihui is an enterprise with long-term growth value. With the increasing digitization of the medical industry, we believe that liangyihui can continue to provide efficient and professional solutions for pharmaceutical enterprises and hospitals in the future, and become a leading service provider in the vertical segmentation of cancer.